Psybio Therapeutics Corp
XTSX:PSYB
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CA |
P
|
Psybio Therapeutics Corp
XTSX:PSYB
|
809k CAD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
201.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
43.7B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
280B CNY |
Loading...
|
|
| DE |
|
BioNTech SE
NASDAQ:BNTX
|
25.6B USD |
Loading...
|
|
| US |
|
United Therapeutics Corp
NASDAQ:UTHR
|
20.9B USD |
Loading...
|
|
| US |
|
Incyte Corp
NASDAQ:INCY
|
20.9B USD |
Loading...
|
|
| DK |
|
Genmab A/S
CSE:GMAB
|
121.4B DKK |
Loading...
|
|
| US |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
18.2B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Psybio Therapeutics Corp
Glance View
PsyBio Therapeutics Corp. engages in the development of drugs intended for the treatment of mental health challenges and other disorders. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2011-02-08. The firm is developing a new class of drugs intended for the treatment of mental health challenges and other disorders. The firm is in the process of developing its portfolio of product candidates for sale in the pharmaceutical industry. The company has developed a technology platform that enables the generation of its formulation for its lead compound psilocybin, biosynthetic psilocybin, and other targeted tryptamines through a biosynthetic process using genetically modified bacteria through collaboration with Miami University-based in Oxford, Ohio. The firm utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon, which to develop precursors and analogs, both naturally and non-naturally occurring.
